Safety and Efficacy of IBI322 in Chinese Subjects With Advanced Malignant Tumors

NCT04328831 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

94

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignancies

Interventions

BIOLOGICAL: IBI322

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.